510(k) vs PMA vs De Novo: Which FDA Pathway Is Right for Your Device?

We explain the differences among 510(k), De Novo, and PMA pathways, mapping them to your device’s risk, novelty, predicate availability, and intended use so you can choose the right route. We outline key requirements and evidence for each option—predicate comparisons, ISO 14971 risk analysis, bench/software performance testing, human factors validation, labeling, and when clinical trials and manufacturing validation are required—along with typical timelines and common pitfalls that drive delays and costs. We provide a decision framework and questions (predicate existence, risk class, technological novelty, evidence level) to help your team avoid RTA outcomes, redesigns, and rework. We emphasize starting regulatory strategy early and integrating design controls (21 CFR Part 820), usability, verification and validation, and risk management into your development plan to align with FDA expectations. We show how our integrated design, engineering, human factors, prototyping, and regulatory consulting support can align your product and submission strategy from day one, reducing uncertainty and accelerating your market entry.